Non-motor symptoms (NMS) represent a major challenge in Parkinson's disease (PD) management, affecting up to 90% of patients and often preceding motor symptoms by years or decades. These symptoms significantly impact quality of life and include neuropsychiatric disturbances, sleep disorders, autonomic dysfunction, cognitive impairment, and sensory abnormalities. The pathophysiology involves multiple neurotransmitter systems beyond the dopaminergic pathway, including cholinergic, serotonergic, and noradrenergic systems, reflecting the diffuse neuropathology of PD that extends beyond the substantia nigra.
Non-motor symptoms affect up to 90% of PD patients and include:
- Depression and anxiety
- Psychosis and hallucinations
- Sleep disorders
- Autonomic dysfunction
- Cognitive impairment
- Sensory symptoms
| Neurotransmitter |
Associated NMS |
Brain Regions Affected |
| Dopamine |
Psychosis, impulsivity |
Mesocortical, mesolimbic pathways |
| Acetylcholine |
Cognitive impairment, RBD |
Basal forebrain, pedunculopontine nucleus |
| Serotonin |
Depression, anxiety |
Raphe nuclei, limbic system |
| Norepinephrine |
Orthostatic hypotension, apathy |
Locus coeruleus |
| Histamine |
Sleep disturbance, cognition |
Tuberomammillary nucleus |
Many NMS appear years before motor diagnosis:
- REM Sleep Behavior Disorder (RBD): May precede motor symptoms by 10-20 years
- Hyposmia/anosmia: Present in up to 90% of PD patients at diagnosis
- Constipation: Common prodromal feature
- Depression: Risk factor and early symptom
¶ Depression and Anxiety
Depression affects approximately 40-50% of PD patients and is associated with significantly reduced quality of life. The underlying mechanisms include dopaminergic mesolimbic pathway dysfunction, serotonergic raphe nuclei involvement, and neuroinflammatory processes.
First-line Treatments:
- SSRIs: Sertraline (50-200 mg/day), Escitalopram (10-20 mg/day), Citalopram (20-40 mg/day)
- Sertraline shows good evidence for efficacy and tolerability
- Escitalopram may have faster onset of action
Second-line Treatments:
- SNRIs: Venlafaxine (75-225 mg/day), Duloxetine (30-60 mg/day)
- Particularly useful if depression accompanies neuropathic pain
- Venlafaxine extended-release preferred
Third-line and Adjunct Treatments:
- TCAs: Nortriptyline (25-75 mg at bedtime)
- Most effective but requires caution for orthostatic hypotension
- Useful for comorbid insomnia or pain
- Bupropion: May be preferred if fatigue is prominent
- Mirtazapine: Useful for insomnia and poor appetite
Dopamine Agonists:
- Pramipexole and rotigotine may improve mood in some patients
- Particularly effective for apathy-depression spectrum
Special Considerations:
- ECT: For severe, treatment-resistant depression
- Safe in PD patients with motor fluctuations
- May temporarily worsen motor symptoms
- TMS: Emerging role for treatment-resistant cases
- Psychotherapy: CBT effective as adjunct to pharmacotherapy
Drug Interactions:
- SSRIs + MAO-B inhibitors: Serotonin syndrome risk (rare with modern doses)
- TCA + anticholinergics: Additive cognitive effects
¶ Psychosis and Hallucinations
PD psychosis affects 20-40% of patients and is a major cause of nursing home placement. Visual hallucinations are most common, often with retained insight early in disease.
Management Algorithm:
-
Rule out precipitating factors:
- Urinary infection
- Metabolic encephalopathy
- Medication-induced (anticholinergics, amantadine, dopamine agonists)
-
Reduce antiparkinsonian medications:
- Reduce or discontinue anticholinergics
- Reduce amantadine
- Simplify dopaminergic therapy
- Consider levodopa monotherapy
-
Add antipsychotic therapy:
Pimavanserin (Nuplazid):
- FDA-approved for PD psychosis (2016)
- 5-HT2A inverse agonist, minimal D2 receptor activity
- No worsening of motor symptoms in clinical trials
- Dose: 34 mg once daily
- 34% reduction in SAPS-PD scores vs placebo
- Most common adverse effects: peripheral edema, nausea
Quetiapine:
- Off-label first-line due to established use
- Low D2 receptor occupancy at lower doses
- Dose: 12.5-150 mg at bedtime
- May cause orthostatic hypotension
- Limited efficacy data from RCTs
Clozapine:
- Most effective antipsychotic for PD psychosis
- Dose: 6.25-50 mg at bedtime
- Requires weekly ANC monitoring for first 6 months
- Risk of agranulocytosis (approximately 0.5%)
- Reserved for refractory cases
Other Agents:
- Risperidone: Effective but may worsen motor symptoms
- Olanzapine: Effective but significant motor worsening
- Aripiprazole: Partial dopamine agonist, mixed results
- Ondansetron: 5-HT3 antagonist, emerging evidence
Apathy affects 30-40% of PD patients and is distinct from depression, though they frequently co-occur. Apathy involves diminished goal-directed behavior without sadness or anhedonia.
Treatment Approaches:
-
Optimize dopaminergic therapy:
- Increase levodopa dose if motor symptoms uncontrolled
- Add or adjust dopamine agonist
- Consider continuous dopaminergic stimulation
-
Pharmacological interventions:
- Methylphenidate: 10-40 mg/day
- Evidence for amotivation in advanced PD
- May improve gait and mobility
- Modafinil: 100-400 mg/day
- Limited evidence for apathy
- Rivastigmine: May help cognitive aspects of apathy
- Atomoxetine: Mixed evidence
-
Non-pharmacological:
- Structured activity programs
- Behavioral activation therapy
- Caregiver education and support
Important Notes:
- SSRIs may worsen apathy in some patients
- Distinguish from depression (different treatment approach)
- Apathy may improve with dopaminergic therapy optimization
Sleep disturbances are among the most common and disabling NMS, affecting 60-90% of PD patients. Multiple mechanisms contribute, including neurodegeneration of sleep-regulating nuclei, medication effects, and motor symptoms.
RBD is characterized by loss of atonia during REM sleep, leading to dream enactment behaviors. It is a strong prodromal marker for synucleinopathies and may precede PD diagnosis by decades.
Pathophysiology:
- Neurodegeneration of sublaterodorsal nucleus
- Loss of glycinergic/GABAergic inhibition
- Often indicates diffuse synuclein pathology
Treatment:
First-line:
- Melatonin: 3-12 mg at bedtime
- Recommended as first-line
- Well-tolerated with minimal side effects
- May require dose titration
Second-line:
- Clonazepam: 0.25-1 mg at bedtime
- Effective in 80% of patients
- Can cause sedation, dizziness, worsening of OSA
- Use with caution in elderly
Third-line:
- Pramipexole: May help in some patients
- Particularly if comorbid RBD/Parkinsonism
- Variable response
Additional Considerations:
- Safety modifications: Bed rails, padding floor
- Treat comorbid sleep apnea
- Sleep partner education
EDS affects up to 50% of PD patients and significantly impacts quality of life, safety, and driving ability.
Assessment:
- Epworth Sleepiness Scale (ESS)
- Multiple Sleep Latency Test (MSLT) if narcolepsy suspected
- Rule out nocturnal sleep fragmentation
Treatment:
Pharmacological:
- Modafinil: 100-400 mg daily
- Most commonly prescribed
- Variable efficacy evidence
- Methylphenidate: 5-10 mg BID
- More robust evidence
- May worsen insomnia
- Caffeine: 100-200 mg TID
- Over-the-counter option
- May help mild cases
- Armodafinil: 150-250 mg daily
- Longer half-life than modafinil
Non-pharmacological:
- Optimize nighttime sleep
- Scheduled naps (20-30 minutes)
- Sleep hygiene optimization
- Treat sleep apnea
Important:
- Driving safety assessment critical
- Counsel patients about EDS and driving
Difficulty with sleep initiation and maintenance affects up to 60% of PD patients.
Treatment:
-
Cognitive Behavioral Therapy for Insomnia (CBT-I):
- Most effective non-pharmacological treatment
- Sleep restriction therapy
- Stimulus control
- Cognitive restructuring
-
Pharmacological:
- Zolpidem: 5-10 mg at bedtime (use cautiously)
- Eszopiclone: 1-3 mg
- Temazepam: 7.5-30 mg
- Melatonin: 1-10 mg (especially for circadian rhythm issues)
-
Medication review:
- Reduce or discontinue sedating medications
- Time dopaminergic medications appropriately
-
Rotigotine patch:
- May improve sleep continuity
- Provides continuous dopaminergic stimulation
PD patients commonly exhibit circadian dysregulation, contributing to sleep-wake cycle disturbances.
Treatment:
- Bright light therapy: Morning exposure (2000-10000 lux)
- Melatonin: 0.5-5 mg 2-3 hours before desired bedtime
- Regular sleep schedule
- Timed exercise
Autonomic failure in PD results from peripheral and central autonomic nervous system involvement, affecting cardiovascular, gastrointestinal, urinary, and sexual function.
OH affects 30-50% of PD patients and results from sympathetic denervation and medication effects.
Diagnosis:
- SBP drop ≥20 mmHg or DBP drop ≥10 mmHg within 3 minutes of standing
- Consider 24-hour ABPM for confirmation
- Rule out hypovolemia, cardiac pump failure
Non-pharmacological Management:
- Increase salt intake (6-10 g/day)
- Increase fluid intake (2-3 L/day)
- Compression stockings (waist-high, 30-40 mmHg)
- Head-of-bed elevation (10-30 degrees)
- Slow positional changes
- Avoid large meals
- Exercise in recumbent position
Pharmacological Treatment:
| Medication |
Dose |
Mechanism |
| Midodrine |
2.5-10 mg TID |
α1-agonist |
| Fludrocortisone |
0.1-0.2 mg daily |
Mineralocorticoid |
| Droxidopa (Northera) |
100-600 mg TID |
Norepinephrine prodrug |
| Pyridostigmine |
30-60 mg TID |
AChE inhibitor (mild) |
Droxidopa (Northera):
- FDA-approved for neurogenic OH
- Effective in PD
- Monitor for supine hypertension
- Dose titration required
Supine Hypertension:
- Common adverse effect of treatment
- Elevate head of bed
- Avoid taking medication before bed
- Consider short-acting agents
Bladder dysfunction affects 30-70% of PD patients, typically manifesting as overactive bladder with urgency, frequency, and nocturia.
Evaluation:
- Urodynamic studies to confirm detrusor overactivity
- Rule out obstruction
- Voiding diary
Treatment:
Overactive Bladder:
- Anticholinergics: Oxybutynin (2.5-10 mg BID/TID), Tolterodine (2-4 mg BID), Solifenacin (5-10 mg daily)
- Use cautiously - may worsen cognitive function
- Trospium less CNS penetration
- β3-Agonist: Mirabegron (25-50 mg daily)
- Better cognitive profile
- May raise blood pressure
Detrusor Underactivity:
- Catheterization: Intermittent or indwelling for severe retention
Nocturia:
- Desmopressin nasal spray (10-40 μg nightly)
- Monitor for hyponatremia
GI symptoms affect nearly all PD patients at some point, reflecting the diffuse nature of Lewy body pathology in the enteric nervous system.
Constipation (most common):
- Fiber supplementation: 25-30 g/day
- Osmotic laxatives: Polyethylene glycol, lactulose
- Stimulant laxatives: Senna, bisacodyl (as needed)
- Secretagogues: Lubiprostone (8-24 μg BID)
- Chloride channel activator
- Effective in PD
- Prokinetics: Mosapride (not available in US)
- Botulinum toxin: For severe cases
Nausea:
- Domperidone: 10-20 mg TID (not available in US)
- Ondansetron: 4-8 mg as needed
- Meclizine: 25-50 mg as needed
- Time medications to avoid peaks
Dysphagia:
- Swallowing evaluation
- Texture-modified diet
- Swallowing therapy with speech pathologist
- Botulinum toxin: To cricopharyngeus if spastic
Gastroparesia:
- Metoclopramide (caution - may worsen parkinsonism)
- Domperidone
Sexual dysfunction affects 50-80% of PD patients, involving both physical and psychological factors.
Erectile Dysfunction:
- PDE5 inhibitors: Sildenafil (25-100 mg), Tadalafil (5-20 mg)
- Generally safe in PD
- Monitor for hypotension with dopaminergic drugs
- Vacuum devices
- Intracavernosal injections: For refractory cases
Decreased Libido:
- Optimize dopaminergic therapy
- Testosterone replacement if deficient
- Psychological counseling
Hyper sexuality:
- Often medication-induced (dopamine agonists)
- Reduce or discontinue implicated medication
Cognitive dysfunction ranges from mild cognitive impairment (MCI-PD) to Parkinson's disease dementia (PDD), affecting 30-50% of patients over disease course.
MCI-PD affects 25-30% of newly diagnosed PD patients and progresses to dementia in 30-50% within 5-10 years.
Assessment:
- MoCA (Montreal Cognitive Assessment) - more sensitive than MMSE
- Detailed neuropsychological testing
- Evaluate executive function, attention, memory, visuospatial function
Treatment:
- Rivastigmine: May improve global cognition
- Exercise: Moderate evidence
- Cognitive training: May help maintain function
- Treat comorbidities: Depression, sleep, medication effects
- Medication review: Reduce anticholinergics, sedatives
PDD develops in 30-50% of patients with disease duration >10 years, characterized by attentional and executive deficits prominently.
Cholinesterase Inhibitors:
| Drug |
Dose |
Evidence |
| Rivastigmine |
Transdermal 4.6-13.3 mg/24h; Oral 1.5-12 mg/day |
Strongest evidence |
| Donepezil |
5-10 mg daily |
Mixed evidence |
| Galantamine |
8-24 mg/day |
Limited evidence |
Rivastigmine:
- FDA-approved for PDD
- First-line treatment
- Transdermal formulation preferred
- Start low, titrate slowly
- GI side effects common with oral formulation
Memantine:
- NMDA antagonist
- 10 mg BID
- May provide modest benefit
- Combination with cholinesterase inhibitor possible
Non-pharmacological:
- Exercise programs
- Cognitive stimulation
- Caregiver education
- Environmental modifications
- Sleep optimization
Important Considerations:
- PDD vs Dementia with Lewy Bodies (DLB): Overlapping features
- DLB: Dementia precedes parkinsonism or within 1 year
- PDD: Parkinsonism precedes dementia by >1 year
¶ Pain and Dysesthesia
Pain affects 40-60% of PD patients and has multiple etiologies.
Classification (based on Ford):
-
Musculoskeletal pain:
- Related to rigidity, dystonia
- Treatment: Physical therapy, exercise, dopaminergic adjustment
-
Neuropathic pain:
- burning, tingling
- Treatment: Gabapentin, Pregabalin, Duloxetine
-
Dystonic pain:
- Related to OFF periods, dyskinesias
- Treatment: Optimize dopaminergic therapy, botulinum toxin
-
Central pain:
- Unspecified burning, aching
- Treatment: Tricyclic antidepressants, opioids (cautiously)
Pharmacological Options:
- Gabapentin: 300-1800 mg daily
- Pregabalin: 75-300 mg BID
- Duloxetine: 30-60 mg daily
- Tramadol: For refractory cases (caution for dependence)
- Oxycodone: For severe refractory pain (avoid if possible)
Olfactory dysfunction affects up to 90% of PD patients and is a key prodromal marker.
Assessment:
- UPSIT (University of Pennsylvania Smell Identification Test)
- Often present years before diagnosis
Treatment:
- Intranasal theophylline: Clinical trials ongoing
- Smell training therapy: Limited evidence
- Use of rose, lemon, clove, eucalyptus odors
- 2 times daily for 12+ weeks
- Vitamin B12: If deficient
- Intranasal nerve growth factor: Experimental
- SSRIs + MAO-B inhibitors: Serotonin syndrome risk (rare with modern doses, but monitor)
- Anticholinergics: Cognitive worsening - avoid in elderly
- QT-prolonging agents: Cardiac risk with pimavanserin - check baseline ECG
- Droperidol + antipsychotics: QT prolongation risk
- Anticholinergics + bladder medications: Additive effects
- Identify and treat underlying causes
- Optimize dopaminergic therapy
- Target specific symptoms
- Non-pharmacological interventions
- Multidisciplinary care
The study of Non-Motor Symptoms in Parkinson's Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration, including the widespread nature of alpha-synuclein pathology beyond the substantia nigra. Key discoveries include the identification of prodromal markers like RBD and hyposmia, the role of multiple neurotransmitter systems in NMS pathogenesis, and the development of targeted treatments like pimavanserin. This understanding continues to drive therapeutic development and improve patient care.
- Schapira AHV, et al. Nat Rev Dis Primers. 2023;9(1):21
- Seppi K, et al. Mov Disord. 2019;34(7):991-1026
- Goldman JG, et al. Nat Rev Neurol. 2018;14(10):577-588
- Poewe W, et al. Nat Rev Dis Primers. 2017;3:17013
- Martinez-Martin P, et al. Lancet Neurol. 2024;23(1):54-68
- Chaudhuri KR, et al. Nat Rev Neurol. 2023;19(2):73-84
- Weintraub D, et al. Mov Disord. 2020;35(5):816-825
- Kalia LV, et al. Lancet. 2015;386(9996):896-912
- Pfeiffer RF. Autonomic Dysfunction in Parkinson's Disease. Mov Disord. 2023
- Postuma RB, et al. Sleep Disorders in Parkinson's Disease. Lancet Neurol. 2024
- Aarsland D, et al. Parkinson's Disease Dementia. Nat Rev Dis Primers. 2023
- Stoker TB, et al. Depression in Parkinson's Disease. Lancet Psychiatry. 2024
- Friedman JH, et al. Pimavanserin for Parkinson's Disease Psychosis. J Clin Psychopharmacol. 2024
- Kalia LV, et al. Clinical Approach to Apathy in Parkinson's Disease. Mov Disord. 2023
- Jankovic J. Parkinson's Disease: Clinical Features and Diagnosis. J Neurol Neurosurg Psychiatry. 2024